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Type 2 diabetes mellitus (T2DM) is a progressive disease characterised by beta cell dysfunction and insulin resistance. Beta cell 
dysfunction progresses to beta cell failure. Many patients with T2DM are managed with oral agents until complications develop. 
‘Clinical inertia’ in T2DM, defined as lack of initiation or intensification of therapy when clinically indicated, is common among 
clinicians. Patients are exposed to hyperglycaemia for a long time resulting in glucotoxicity to beta cells, leading to further beta 
cell deterioration. The traditional approach to the management of T2DM is lifestyle change, diet, exercise, weight loss, oral agents 
and, lastly, insulin. This traditional approach is usually carried out step-by-step and at a slow pace, with insulin offered as a last 
option. By the time insulin therapy is initiated, complications have already developed. It is, therefore, important for clinicians 
to be aware of the importance of initiating insulin therapy early to prevent poor glycaemic control and the development of 
diabetes-related complications.
Introduction
Type 2 diabetes mellitus (T2DM) is an insulin-insufficient disease 
characterised pathophysiologically by beta cell dysfunction and 
insulin resistance.1 Glycaemic control is important in the 
management of T2DM to prevent diabetes-related 
complications.1–4 Early in the onset of T2DM there is development 
of relative insulin deficiency and, later, absolute insulin deficiency.1 
Therefore, when a patient is diagnosed with T2DM, the degree of 
deficiency depends on the stage of the disease at which the 
diagnosis has been made.1 Early in the natural course of T2DM, 
patients develop insulin resistance, hyperglycaemia and 
hyperinsulinemia.3,5 As the disease progresses, patients develop 
beta cell failure with hyperglycaemia and hypoinsulinemia.3,5 
Most of the patients are diagnosed at the late stage where there is 
hyperglycaemia and hypoinsulinemia, usually with beta cell 
function declined by 50%.5–8 It can be extrapolated from the 
United Kingdom Prospective Diabetes Study (UKPDS) that beta 
cell dysfunction could commence 15 years before diagnosis.9 At 
this late stage, most patients require exogenous insulin therapy 
for optimal glycaemic control.5 Management of T2DM involves 
addressing the pathophysiology of the disease.1,10 The following 
drug classes are important in its management: sulfonylureas, 
biguanides, meglitinides, alpha-glucosidase inhibitors, 
thiazolidinediones, insulin, dipeptidyl peptidase 4 (DPP IV) 
inhibitors, glucagon-like peptide-1 (GLP-I) analogues and sodium-
glucose cotransporter 2 inhibitors.1,11 Despite the availability of 
these drug classes, few patients attain glycaemic control.2,3,7 This is 
due to the progressive nature of the disease. Most patients with 
T2DM will eventually need insulin therapy for glycaemic 
control.8,12,13 Insulin is the only drug with an unlimited percentage 
of HbA1c reduction.4 Doses of insulin can be titrated until an 
individualised glycaemic target is reached.4
It is, therefore, important for clinicians to understand the 
importance of early insulin initiation so that glycaemic control 
can be achieved early and consequently prevent diabetes-
related complications.
Rationale for the use of early insulin therapy in 
T2DM
Physiologically, fasting glucose is controlled by endogenous basal 
insulin secretion, whereas postprandial glucose is controlled by 
both endogenous basal and bolus insulin secretions.14 The 
management of T2DM is to try to simulate the normal physiology 
of insulin secretion. Insulin therapy in T2DM results in beta cell rest 
and prevents toxic effects of hyperglycaemia on beta cells.15,16 
Insulin reduces excessive secretory demands on beta cells, is anti-
inflammatory, has anti-apoptosis effects and thus results in beta 
cell recovery.14,15 The anti-inflammatory effect of insulin benefits 
vascular endothelium, reducing cardiovascular risk.14,15 Insulin has 
been proved to preserve beta cells and improve beta cell 
function.15 When insulin therapy in newly diagnosed T2DM was 
compared with oral agents in terms of beta cell preservation and 
glycaemic remissions,8,15,17 insulin showed favourable results in 
terms of recovery and maintenance of beta cell function, and 
glycaemic remissions.8,15,17 The United Kingdom Prospective 
Diabetes Study (UKPDS) showed that if a patient is diagnosed with 
T2DM and is managed with oral agents only, in six years he or she 
will need insulin therapy for glycaemic control.9 When the insulin 
and metformin regimen was compared with triple oral 
hypoglycaemic agents, the insulin and metformin regimen 
showed better glycaemic control than triple therapy, with less 
hypoglycaemia and weight gain.16 A study was conducted where 
short-term insulin therapy was evaluated in terms of beta cell 
preservation and beta cell function in patients newly diagnosed 
with T2DM. After multiple insulin injections over two to three 
weeks, euglycemia was achieved in 90% of subjects who 
completed the study. Insulin was withdrawn and patients were 
managed with diet and exercise only.8,18 Most of the patients 
maintained euglycemia for more than 12  months.18 This study 
showed that insulin preserved and improved beta cell function 
and resulted in improvement of endogenous insulin secretion.18 A 
study was conducted where insulin monotherapy and metformin 
monotherapy were individually compared with an insulin and 
metformin regimen.19 It was shown that the insulin and metformin 
regimen achieved better glycaemic control as compared with 
both drugs used individually.19
Indications for early insulin therapy in T2DM
Insulin therapy is considered as initial therapy in the management 
of T2DM when the disease is diagnosed in a patient with clinical 
features of catabolism such as weight loss, in patients with 
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fasting glucose of more than 14 mmol/l, ketonuria or ketoacidosis, 
HbA1c of more than 10%, random glucose of more than 
16.7  mmol/l, women with gestational T2DM not controlled 
through diet alone, and in patients who, after discussion of 
options of therapy, wish to start insulin as initial therapy.4,9,10,20–22 
Insulin is also considered in patients on maximum oral 
hypoglycaemic agents with individualised glycaemic target 
unmet.10–12,20–22
Barriers to early insulin initiation in T2DM
Clinicians at times are reluctant to initiate insulin therapy in 
patients with T2DM despite poor glycaemic control. The common 
clinician-related barriers are fear of hypoglycaemia, weight gain 
and misconception that insulin causes cardiovascular disease. 
The patient-related barriers are fear of needles, fear of disease 
progression and the misconception that injection is a sign of 
failure with treatment or a sign that the disease is more severe 
than that of patients taking oral agents.3,16,23,24 All these barriers to 
insulin therapy should be addressed on diagnosis of T2DM.
Practical strategies for early insulin initiation
Insulin strategies
Patients with T2DM experience decline in beta cell function and, 
with time, need exogenous insulin therapy.11 Before insulin 
therapy is initiated there are questions that the clinician should 
address.25 First, how far from the individualised goal is the patient? 
According to several guidelines in the management of T2DM, 
target fasting glucose, postprandial glucose and HbA1c must be 
individualised.18,21 In patients who are young, low risk, newly 
diagnosed with T2DM and who have no cardiovascular disease, 
target HbA1c should be less than 6.5%, fasting glucose should be 
between 4  mmol/l and 7  mmol/l, and postprandial glucose 
should be between 4.4 mmol/l and 7.8 mmol/l. In the majority of 
patients with T2DM, target HbA1c should be less than 7%, fasting 
sugar between 4 mmol/l and 7 mmol/l and postprandial glucose 
between 5  mmol/l and 10  mmol/l. In patients who are elderly, 
high risk with poor short-term prognosis and who have 
hypoglycaemic unawareness, target HbA1c should be less than or 
equal to 8%, fasting glucose should be between 4  mmol/l and 
7  mmol/l, and postprandial glucose should be less than 
12 mmol/l.10,21,22
Second, if insulin is initiated, which oral agent should be stopped? 
Patients with T2DM are usually managed with metformin and 
sulfonylurea. Pathophysiologically, when giving insulin to 
patients on metformin and sulfonylureas, sulfonylureas may be 
discontinued or may be continued, depending on the glycaemic 
control of the patient or insulin strategy used.
Lastly, what type of insulin programme should be started? Insulin 
strategies available are biphasic premixed insulin, basal insulin 
and basal-bolus insulin therapy. Biphasic premixed insulin added 
to metformin was compared with basal insulin added to 
metformin in terms of HbA1c. HbA1c was significantly reduced in 
patients on biphasic premixed insulin added to metformin.26 
Basal-bolus insulin therapy was compared with biphasic premixed 
insulin therapy in patients who failed on oral hypoglycaemic 
agents or who failed on oral hypoglycaemic agents combined 
with basal insulin therapy.27 There was no difference between the 
two regimens in terms of HbA1c reduction, fasting and 
postprandial glucose reduction, weight gain and hypoglycaemic 
events.27 The problem is that biphasic premixed insulin therapy is 
not physiological and the doses of intermediate-acting insulin 
and short-acting insulin are not flexible.28 The one dose of 
biphasic premixed insulin cannot be adjusted without affecting 
the other dose.28 Basal-bolus insulin therapy, though physiological, 
has the disadvantage of multiple injections.29 Which of these 
insulin strategies is chosen depends on HbA1c level. In a newly 
diagnosed T2DM patient, if HbA1c is between 7% and 10% or it is 
1% to 2% above the individualised target, and insulin therapy is 
indicated, bedtime basal insulin should be initiated together with 
metformin and sulfonylurea.17,30 In a newly diagnosed T2DM 
patient, if HbA1c is greater than 10% or it is 2% above the 
individualised target, and insulin therapy is indicated, basal-bolus 
insulin therapy or biphasic premixed insulin therapy should be 
initiated together with metformin.7,18,26,29,30 In a patient already on 
metformin and sulfonylurea, if HbA1c is between 7% and 10% or 
it is 1% to 2% above the individualised target, basal insulin may 
be added. If a patient is already on bedtime basal insulin plus oral 
agents and HbA1c is greater than 10% or it is 2% above the 
individualised target, it is best to discontinue sulfonylurea, 
continue metformin, and to introduce basal-bolus insulin therapy 
or biphasic premixed insulin therapy.7,18,26,29,30 Whichever insulin 
strategy is considered, fasting glucose, postprandial glucose and 
HbA1c should be assessed, and insulin therapy adjusted 
according to the individualised glycaemic target. The choice of 
insulin strategy must be discussed with the patient and agreed 
on to encourage adherence.
Insulin initiation
When insulin therapy is indicated, the question is always: How is 
insulin therapy initiated? If bedtime insulin therapy is indicated 
and the patient is lean, initiate with 5 to 10u of bedtime insulin, 
and if the patient is obese, initiate with 10 to 15u or initiate with 
0.1–0.2u/kg of bedtime insulin depending on the degree of 
hyperglyceamia.11,21,31 Bedtime insulin therapy is used together 
with oral agents. Monitor fasting blood glucose every morning 
and calculate average fasting glucose every three to seven days 
and increase the bedtime insulin by 2 to 5 units until the fasting 
sugar has reached the individualised target.11,21 If pre-lunch or 
pre-dinner glucose, or both pre-lunch and pre-dinner glucose 
have not reached the individualised target, bolus insulin during 
one or more of the meals can be introduced. If biphasic premixed 
insulin is preferred as the initial therapy or patients have failed to 
reach their target after adding basal insulin therapy to oral agents, 
calculate the total daily insulin requirement by multiplying the 
weight of the patient by 0, 3, then divide the total daily insulin 
into two doses, namely, 2/3 given before breakfast and 1/3 before 
supper. Alternatively, the patient can start with 10u biphasic 
premixed insulin twice a day,21 or take the total insulin calculated 
and give 50% before breakfast and 50% before supper.7 When 
fasting and pre-dinner glucose are controlled, in biphasic 
premixed insulin therapy, monitor postprandial glucose and 
introduce bolus insulin at lunchtime if indicated. If basal-bolus 
insulin therapy is preferred as initial insulin therapy, give half of 
the 24-hour insulin required as basal insulin and then the 
remaining half divided into three as bolus insulin at mealtimes.30,31 
When fasting glucose and postprandial glucose have reached 
individualised targets, monitor HbA1c every three months until 
target is reached. When HbA1c has reached individualised target 
level, monitor it every six months.
Conclusion
T2DM is a common public health problem associated with long-
term complications if not well controlled.1–4,32 Insulin is usually 
used as the last option in the management of T2DM.32 Delay in 
insulin initiation is the common cause of prolonged exposure to 
hyperglycaemia, which results in diabetes-related complications.32 
Initiating insulin early in the management of T2DM will prevent 
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development of these complications. It is, therefore, important 
for clinicians to initiate insulin therapy early so as to reach 
individualised glycaemic targets early, thereby preventing T2DM-
related complications.
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